Abstract: An improved method is provided for treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast. The improvement involves administering the roflumilast topically in a composition having a roflumilast release profile that produces in the patient a flattened plasma concentration time curve and a reduced Cmax relative to oral administration of a PDE4-inhibiting amount of roflumilast. Such disorders include inflammatory disorders such as inflammatory dermatoses, including psoriasis, atopic dermatitis and seborrheic dermatitis. Such disorders also include inflammatory diseases in a variety of organs, especially the lungs (asthma, COPD). Because of reduced side effects with topical administration due to the improved pharmacokinetics (PK) characteristics, it may be possible to provide higher systemic exposures (AUCs) with topical administration, resulting in greater therapeutic efficacy than with the oral route of administration.

Abstract: Methods of dewatering tailings, including tailings streams that may include a clay, ultra-fine particles, or both. The methods may include providing a tailings stream, dewatering the tailings stream with a dewatering apparatus to produce a first cake and a first residual effluent stream, contacting the first residual effluent stream with one or more additives, and dewatering the first residual effluent stream with a solid bowl centrifuge to produce a second cake and a second residual effluent stream. The methods may include providing a tailings stream, contacting the tailings stream with one or more additives, and dewatering the tailings stream with a solid bowl centrifuge to produce a first cake and a first residual effluent stream.

Abstract: An improved method is provided for treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast. The improvement involves administering the roflumilast topically in a composition having a roflumilast release profile that produces in the patient a flattened plasma concentration time curve and a reduced Cmax relative to oral administration of a PDE4-inhibiting amount of roflumilast. Such disorders include inflammatory disorders such as inflammatory dermatoses, including psoriasis, atopic dermatitis and seborrheic dermatitis. Such disorders also include inflammatory diseases in a variety of organs, especially the lungs (asthma, COPD). Because of reduced side effects with topical administration due to the improved pharmacokinetics (PK) characteristics, it may be possible to provide higher systemic exposures (AUCs) with topical administration, resulting in greater therapeutic efficacy than with the oral route of administration.

Abstract: An improved method is provided for treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast. The improvement involves administering the roflumilast topically in a composition having a roflumilast release profile that produces in the patient a flattened plasma concentration time curve and a reduced Cmax relative to oral administration of a PDE4-inhibiting amount of roflumilast. Such disorders include inflammatory disorders such as inflammatory dermatoses, including psoriasis, atopic dermatitis and seborrheic dermatitis. Such disorders also include inflammatory diseases in a variety of organs, especially the lungs (asthma, COPD). Because of reduced side effects with topical administration due to the improved pharmacokinetics (PK) characteristics, it may be possible to provide higher systemic exposures (AUCs) with topical administration, resulting in greater therapeutic efficacy than with the oral route of administration.

Abstract: The present invention relates to cellobiohydrolase variants, polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

Abstract: Methods and systems for classification and recovery of certain solids from streams, such as liquid waste streams. Methods including classification with at least one solid bowl centrifuge, followed by a valorization procedure. The valorization procedure may be a flotation procedure, which may include a single-step or two-step procedure.

Abstract: An improved method is provided for treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast. The improvement involves administering the roflumilast topically in a composition having a roflumilast release profile that produces in the patient a flattened plasma concentration time curve and a reduced Cmax relative to oral administration of a PDE4-inhibiting amount of roflumilast. Such disorders include inflammatory disorders such as inflammatory dermatoses, including psoriasis, atopic dermatitis and seborrheic dermatitis. Such disorders also include inflammatory diseases in a variety of organs, especially the lungs (asthma, COPD). Because of reduced side effects with topical administration due to the improved pharmacokinetics (PK) characteristics, it may be possible to provide higher systemic exposures (AUCs) with topical administration, resulting in greater therapeutic efficacy than with the oral route of administration.

Abstract: An improved a method of treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast. The improvement involves administering the roflumilast topically in a composition having a roflumilast release profile that produces in the patient a flattened plasma concentration time curve and a reduced Cmax relative to oral administration of a PDE4-inhibiting amount of roflumilast. Such disorders include inflammatory disorders such as inflammatory dermatoses, including psoriasis, atopic dermatitis and seborrheic dermatitis. Such disorders also include inflammatory diseases in a variety of organs, especially the lungs (asthma, COPD). Because of reduced side effects with topical administration due to the improved pharmacokinetics (PK) characteristics, it may be possible to provide higher systemic exposures (AUCs) with topical administration, resulting in greater therapeutic efficacy than with the oral route of administration.

Abstract: An improved method is provided for treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast. The improvement involves administering the roflumilast topically in a composition having a roflumilast release profile that produces in the patient a flattened plasma concentration time curve and a reduced Cmax relative to oral administration of a PDE4-inhibiting amount of roflumilast. Such disorders include inflammatory disorders such as inflammatory dermatoses, including psoriasis, atopic dermatitis and seborrheic dermatitis. Such disorders also include inflammatory diseases in a variety of organs, especially the lungs (asthma, COPD). Because of reduced side effects with topical administration due to the improved pharmacokinetics (PK) characteristics, it may be possible to provide higher systemic exposures (AUCs) with topical administration, resulting in greater therapeutic efficacy than with the oral route of administration.

Abstract: The present invention relates to cellobiohydrolase variants having increased thermal activity or thermostability, polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

Abstract: An improved a method of treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast. The improvement involves administering the roflumilast topically in a composition having a roflumilast release profile that produces in the patient a flattened plasma concentration time curve and a reduced Cmax relative to oral administration of a PDE4-inhibiting amount of roflumilast. Such disorders include inflammatory disorders such as inflammatory dermatoses, including psoriasis, atopic dermatitis and seborrheic dermatitis. Such disorders also include inflammatory diseases in a variety of organs, especially the lungs (asthma, COPD). Because of reduced side effects with topical administration due to the improved pharmacokinetics (PK) characteristics, it may be possible to provide higher systemic exposures (AUCs) with topical administration, resulting in greater therapeutic efficacy than with the oral route of administration.

Abstract: Methods of dewatering tailings, including tailings streams that may include a clay, ultra-fine particles, or both. The methods may include providing a tailings stream, dewatering the tailings stream with a dewatering apparatus to produce a first cake and a first residual effluent stream, contacting the first residual effluent stream with one or more additives, and dewatering the first residual effluent stream with a solid bowl centrifuge to produce a second cake and a second residual effluent stream. The methods may include providing a tailings stream, contacting the tailings stream with one or more additives, and dewatering the tailings stream with a solid bowl centrifuge to produce a first cake and a first residual effluent stream.

Abstract: The present invention relates to isolated polypeptides having xylanase activity, catalytic domains, carbohydrate binding modules and polynucleotides encoding the polypeptides, catalytic domains or carbohydrate binding modules. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or carbohydrate binding modules.

Abstract: A fuel cell system including a fuel cell stack, separator and a scavenging reservoir. The fuel cell stack is configured to generate water and reusable fuel. The separator is downstream of and in fluid communication with the fuel cell stack. The separator is configured to separate the water from the reusable fuel. The scavenging reservoir is downstream of and in fluid communication with the separator. The scavenging reservoir is configured to receive the water from the separator. The scavenging reservoir includes an inlet portion, an outlet portion, and a middle portion positioned between the inlet and outlet portions. The middle portion includes a reservoir and a passageway extending there between. The passageway is configured to allow a fluid stream to flow there through when the reservoir is occupied by a frozen fluid.

Abstract: A shoe sole sanitizing assembly includes a housing that has a bottom wall, a top wall and a perimeter wall. The top wall has an opening extending therethrough. A cylinder is rotatably mounted to the housing and extends through the opening. An outer surface of the cylinder is comprised of an adsorptive material. A sanitizing fluid is positioned within the housing and the adsorptive material is in contact with the fluid. The sanitizing fluid coats the cylinder and applies the sanitizing fluid to a bottom of a shoe sole when the shoe sole is moved across the cylinder while the cylinder rotates relative to the housing.

Abstract: The present invention relates to cellobiohydrolase variants, polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of producing and using the variants.

Abstract: The present invention relates to cellobiohydrolase variants, polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of producing and using the variants.

Abstract: The present invention relates to cellobiohydrolase variants having increased thermal activity or thermostability, polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

Abstract: The present invention relates to cellobiohydrolase variants, polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of producing and using the variants.

Abstract: According to the present invention, an apparatus is provided that allows cutting an opening in a material, such as a wall or surface, while accurately controlling the depth of penetration so as not to damage or destroy any existing materials behind the wall or surface, and also without needing equal access behind the wall or surface. In a preferred embodiment of the invention, the apparatus includes a support block assembly having a thickness and at least one primary surface, the at least one primary surface defining a perimeter of the support block assembly; and one or more cutting blades coupled to the support block assembly in at least one location and extending away from the at least one primary surface, the one or more cutting blades being arranged in a closed plane orientation and each being coupled to the support block assembly such that the one or more cutting blades extend away from the at least one primary surface at an inset distance relative to the perimeter of the support block assembly.